Allscripts (MDRX) Outlook Above Estimates
Post# of 42
Posted On: 07/17/2015 4:13:45 AM
Shares of Axovant Sciences Ltd. (AXON) climbed more than 10% in the extended session Thursday ahead of the company's presentation at the Alzheimer's Association International Conference 2015 (AAIC) being held in Washington, D.C. from July 18-23, 2015
AXON will present data of the efficacy of its investigational new drug candidate RVT-101 in Mild-Moderate Alzheimer's Disease. The data will be presented via oral and poster presentations.
The Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research. It works on a global, national and local level to enhance care and support for all those affected by Alzheimer’s and other dementias. The annual Alzheimer's Association International Conference (AAIC) brings together thousands of researchers to share information and findings.
AXON's RVT-101 is an orally administered, potent antagonist of the 5-HT6 serotonin receptor. Antagonism of the 5-HT6 receptor is a novel mechanism of action that promotes the release of acetylcholine, glutamate and other neurotransmitters thought to improve cognition and function in patients suffering from Alzheimer's disease and other forms of dementia.
Brokerage firm JMP Securities initiated coverage on AXON shares with a Market Outperform rating and a price target of $36.00.
AXON is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function.
More about Axovant Sciences Ltd. (AXON) at www.axovant.com
**
According to its preliminary financial results for the second quarter 2015, Allscripts Healthcare Solutions, Inc. (MDRX) expects revenue to be in a range of $350 million to $353 million and non-GAAP earnings per share to be approximately $0.12, exceeding the Capital IQ Consensus Estimate of $0.10 earnings per share on revenues of $347.28 million
MDRX said that its strong preliminary results across all key financial metrics reflect continued improvement in its execution across the enterprise on behalf of the company's clients
MDRX will report its second quarter 2015 financial results after the close of regular stock market hours on Tuesday, August 4, 2015.
MDRX is a leader in healthcare information technology solutions that advance clinical, financial and operational results.
More about Allscripts Healthcare Solutions, Inc. (MDRX) at www.allscripts.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites, expected to be a one-stop shop for the various needs of consumers.
CRWE Network’s business model is based on selling advertising to businesses targeting both locally and nationally
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
AXON will present data of the efficacy of its investigational new drug candidate RVT-101 in Mild-Moderate Alzheimer's Disease. The data will be presented via oral and poster presentations.
The Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research. It works on a global, national and local level to enhance care and support for all those affected by Alzheimer’s and other dementias. The annual Alzheimer's Association International Conference (AAIC) brings together thousands of researchers to share information and findings.
AXON's RVT-101 is an orally administered, potent antagonist of the 5-HT6 serotonin receptor. Antagonism of the 5-HT6 receptor is a novel mechanism of action that promotes the release of acetylcholine, glutamate and other neurotransmitters thought to improve cognition and function in patients suffering from Alzheimer's disease and other forms of dementia.
Brokerage firm JMP Securities initiated coverage on AXON shares with a Market Outperform rating and a price target of $36.00.
AXON is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia, a condition characterized by significant decline in mental capacity and impaired daily function.
More about Axovant Sciences Ltd. (AXON) at www.axovant.com
**
According to its preliminary financial results for the second quarter 2015, Allscripts Healthcare Solutions, Inc. (MDRX) expects revenue to be in a range of $350 million to $353 million and non-GAAP earnings per share to be approximately $0.12, exceeding the Capital IQ Consensus Estimate of $0.10 earnings per share on revenues of $347.28 million
MDRX said that its strong preliminary results across all key financial metrics reflect continued improvement in its execution across the enterprise on behalf of the company's clients
MDRX will report its second quarter 2015 financial results after the close of regular stock market hours on Tuesday, August 4, 2015.
MDRX is a leader in healthcare information technology solutions that advance clinical, financial and operational results.
More about Allscripts Healthcare Solutions, Inc. (MDRX) at www.allscripts.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its growing network of community targeted sites, expected to be a one-stop shop for the various needs of consumers.
CRWE Network’s business model is based on selling advertising to businesses targeting both locally and nationally
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)